Clinical trial
S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients…
NCT00006708 · SWOG Cancer Research Network, Other · Terminated
Key facts
| NCT number | NCT00006708 |
|---|---|
| Title | S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
| Official title | A Randomized Phase III Trial of ICE Chemotherapy With or Without Rituximab for the Treatment of Relapsed or Refractory CD20 Expressing Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients Not Suitable for High Dose Therapy and PBSCT |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, rituximab, carboplatin, etoposide, ifosfamide |
| Enrollment | 7 |
| Start date | Oct 1, 2000 |
| Primary completion | Nov 1, 2002 |
| Completion | Nov 1, 2006 |
| First posted | Mar 17, 2004 |
| Last update posted | Apr 10, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: